Autolus Therapeutics to participate in Investor Conferences through January
04 janv. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Global CAR T-cell Therapy Market Trajectory & Analytics Report 2020-2027 Featuring bluebird bio, CARsgen Therapeutics, Celgene Corp, Gilead Sciences, & Novartis
30 déc. 2020 07h33 HE
|
Research and Markets
Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global CAR T-cell Therapy...
Global CAR-T Pipeline Insight Report 2020: Overview, Landscape, Therapeutic Assessment, Current Treatment Scenario and Emerging Therapies
30 déc. 2020 04h38 HE
|
Research and Markets
Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "CAR-T - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. The "CAR-T - Pipeline Insight, 2020," report...
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting
05 déc. 2020 15h01 HE
|
Autolus Therapeutics plc
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm...
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
30 nov. 2020 07h00 HE
|
Autolus Therapeutics plc
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach...
Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference
17 nov. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Reports Third Quarter 2020 Financial Results and Operational Progress
05 nov. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5
30 oct. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September
08 sept. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Reports Second Quarter 2020 Financial Results and Operational Progress
06 août 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...